Literature DB >> 23506881

The SLC22 family with transporters of organic cations, anions and zwitterions.

Hermann Koepsell1.   

Abstract

The SLC22 family contains 13 functionally characterized human plasma membrane proteins each with 12 predicted α-helical transmembrane domains. The family comprises organic cation transporters (OCTs), organic zwitterion/cation transporters (OCTNs), and organic anion transporters (OATs). The transporters operate as (1) uniporters which mediate facilitated diffusion (OCTs, OCTNs), (2) anion exchangers (OATs), and (3) Na(+)/zwitterion cotransporters (OCTNs). They participate in small intestinal absorption and hepatic and renal excretion of drugs, xenobiotics and endogenous compounds and perform homeostatic functions in brain and heart. Important endogeneous substrates include monoamine neurotransmitters, l-carnitine, α-ketoglutarate, cAMP, cGMP, prostaglandins, and urate. It has been shown that mutations of the SLC22 genes encoding these transporters cause specific diseases like primary systemic carnitine deficiency and idiopathic renal hypouricemia and are correlated with diseases such as Crohn's disease and gout. Drug-drug interactions at individual transporters may change pharmacokinetics and toxicities of drugs.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506881     DOI: 10.1016/j.mam.2012.10.010

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  123 in total

Review 1.  Understanding transport by the major facilitator superfamily (MFS): structures pave the way.

Authors:  Esben M Quistgaard; Christian Löw; Fatma Guettou; Pär Nordlund
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-13       Impact factor: 94.444

2.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

3.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

Review 4.  Structural insights into the transport of small molecules across membranes.

Authors:  Nicholas Noinaj; Susan K Buchanan
Journal:  Curr Opin Struct Biol       Date:  2014-03-28       Impact factor: 6.809

5.  Salinity stress-induced differentially expressed miRNAs and target genes in sea cucumbers Apostichopus japonicus.

Authors:  Yi Tian; Yanpeng Shang; Ran Guo; Yaqing Chang; Yanan Jiang
Journal:  Cell Stress Chaperones       Date:  2019-05-27       Impact factor: 3.667

6.  The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Authors:  Joao N Dos Santos Pereira; Sina Tadjerpisheh; Manar Abu Abed; Ali R Saadatmand; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

7.  Cytosolic calcium measurements in renal epithelial cells by flow cytometry.

Authors:  Wing-Kee Lee; Thomas Dittmar
Journal:  J Vis Exp       Date:  2014-10-28       Impact factor: 1.355

Review 8.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 9.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 10.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.